Rapid Analysis of Infections by Spectrometry of Exhaled Breath
NCT ID: NCT03299608
Last Updated: 2024-07-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
246 participants
OBSERVATIONAL
2019-06-21
2025-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Sputum Screening Test to Rule-out Pneumonia at an Early Stage
NCT03256604
Detecting Respiratory Viruses in Upper and Lower Respiratory Tract Samples
NCT01597089
Recognition of Serious Infections in the Elderly
NCT04516187
DNA-based Testing in BAL of Lung Transplant Recipients With Suspected Non-viral Lower Respiratory Tract Infection
NCT02568358
Innate Immune Response of Blood Cells in Patients With Pneumonia
NCT03231670
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Breath analysis
Spectrometric analysis of exhaled breath as screening for opportunistic respiratory infections
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* One of the following diagnoses:
* De novo, refractory or relapsed AML/MDS receiving intensive chemotherapy
* De novo, refractory or relapsed ALL/T-lymphoblastic lymphoma receiving intensive chemotherapy
* Aplastic anemia requiring ATG therapy
* Any patient admitted for either autologous hematopoietic stem cell transplantation. Transplantation may not have been performed at time of enrolment.
* Any patient admitted with allogeneic hematopoietic stem cell transplantation within the last year, or planned during this admission.
* Written informed consent obtained from the patient
* Signs of active respiratory infection
* If previously enrolled: incomplete clearance of all signs of respiratory infection (both clinically, microbiologically and radiologically).
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Universitaire Ziekenhuizen KU Leuven
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospitals Leuven
Leuven, , Belgium
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
S60785
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.